STOCK TITAN
  1. Home
  2. Sec-filings
  3. CANF
  4. [EFFECT] Can-Fite BioPharma Ltd. SEC Filing

[EFFECT] Can-Fite BioPharma Ltd. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: March 31, 2026
Accession Number: 0001213900-26-036571
Submission Type: POS AM
CIK: 0001536196
Company Name: Can-Fite BioPharma Ltd.
File Number: 333-269485

Source: View Original Filing on SEC EDGAR

Can-Fite BioPharma Ltd.

NYSE:CANF

View CANF Stock Overview →

CANF Rankings

#6599 Ranked by Market Cap
N/A Ranked by Dividends

CANF Latest News

Mar 30, 2026
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
Mar 26, 2026
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
Mar 17, 2026
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
Mar 4, 2026
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Mar 4, 2026
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

CANF Latest SEC Filings

Mar 30, 2026
[F-3] Can-Fite BioPharma Ltd. Foreign Issuer Shelf Registration
Mar 30, 2026
[POS AM] Can-Fite BioPharma Ltd. SEC Filing
Mar 30, 2026
[POS AM] Can-Fite BioPharma Ltd. SEC Filing
Mar 30, 2026
[6-K] Can-Fite BioPharma Ltd. Current Report (Foreign Issuer)
Mar 26, 2026
[20-F] Can-Fite BioPharma Ltd. Files Annual Report (Foreign Issuer)

CANF Stock Data

6.53M
2.14M
Biotechnology
Healthcare
Link
Israel
Ramat Gan